News & Updates

New long-term data confirm safety, efficacy of atogepant for migraine prevention
New long-term data confirm safety, efficacy of atogepant for migraine prevention
27 Apr 2024 byJairia Dela Cruz

Daily use of the oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant to prevent migraine is associated with a favourable safety profile and sustained improvements in efficacy outcomes, according to the 52-week data from an ongoing, open-label, 156-week safety extension study.

New long-term data confirm safety, efficacy of atogepant for migraine prevention
27 Apr 2024